-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75

Benzinga·08/13/2026 10:20:56
Listen to the news
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.